Content area
Full Text
Nondrug Therapy TMS Targets Depression
Mission Viejo-based MYnd Analytics Inc. (Nasdaq: MYND) is in the business of behavioral health. Its flagship platform Peer provides a personalized patient report using electroencephalography, which monitors brain electrical activity.
MYnd, which earlier filed patent applications in the U.S. and Canada related to its acquisition of patient responsivity data for transcranial magnetic stimulation, or TMS, recently announced it received approval in Canada. The patent provides protection through 2029.
"This patent comes on the heels of our recent commercial launch of this technology in both the United States and Canada," said Chief Executive George Carpenter.
TMS is a noninvasive outpatient procedure that uses electricity to stimulate areas of the brain thought to control mood. MYnd plans to offer it as an alternative treatment for patients with depression who've tried one or more antidepressants with no good results.
TMS may not...